Mantadan (Amantadine Hydrochloride)

Amantadine blocks the M2 proton channel of influenza A viruses, stopping viral uncoating and replication. In the central nervous system it antagonises NMDA receptors and increases dopamine release, which helps improve motor symptoms in Parkinson's disease and reduces dyskinesia associated with levodopa therapy.

The appropriate dose of Mantadan is determined by the prescribing clinician based on the specific indication, patient age, renal function, and other clinical factors. Patients should follow the exact regimen provided by their healthcare professional and not adjust the dose on their own.

Safety data for amantadine in pregnancy and lactation are limited. Healthcare providers should weigh potential benefits against possible risks and discuss them with the patient. Women who are pregnant, planning pregnancy, or breastfeeding should consult their physician before using Mantadan.

To place an order, submit an enquiry on the Mantadan product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mantadan (amantadine) differs from neuraminidase inhibitors such as oseltamivir by targeting the viral M2 proton channel rather than the neuraminidase enzyme. This unique mechanism can be advantageous for certain influenza A strains, but resistance patterns and clinical guidelines influence its relative use compared with newer antivirals.

Mantadan should be stored at room temperature, below 25 °C, in its original container to protect it from moisture and direct sunlight. Keeping the product in a dry, stable environment helps maintain its potency throughout the shelf life.

Mantadan is administered orally, typically as a tablet or capsule taken with or without food as directed by a healthcare professional. The exact method of intake, including timing relative to meals, should follow the prescriber's instructions.

Serious risks include neuropsychiatric events such as hallucinations or psychosis, severe skin reactions like Stevens‑Johnson syndrome, cardiac arrhythmias due to QT prolongation, anaphylactic reactions, and significant liver injury. Patients should seek immediate medical attention if any of these symptoms develop.

Mantadan is contraindicated in individuals with known hypersensitivity to amantadine or any of its excipients, patients with severe renal impairment without appropriate monitoring, and those with a history of severe cardiac arrhythmias. Pregnant or breastfeeding women should only use it after thorough risk‑benefit evaluation by their physician.